Innovative Health Care Models Prove Cost-Effective Amidst Pandemic Pressures

By Staff Writer

September 26, 2023

During the COVID-19 pandemic, hospitals faced immense pressure. Singapore was also grappling with a dengue outbreak, adding to the strain on hospital capacity. This situation led to the rapid implementation of novel care models to treat patients with acute, low-severity medical conditions.

Two of these models, the hospital-at-home (HaH) and ambulatory care team (ACT) models, were used to treat patients with dengue and chest pain respectively. The HaH model allowed patients to receive care at home, while the ACT model provided timely care in a clinic-style setting at the hospital’s emergency department.

An economic evaluation aimed to compare the personnel cost of these models with conventional hospital inpatient care. The results showed that the HaH and ACT models used less personnel time, resulting in reduced costs.

The HaH model for treating dengue was found to be slightly cheaper than conventional care, with estimated savings of 18 SGD per case. The ACT model for treating chest pain showed more significant savings, with an estimated reduction of 126 SGD per case.

These innovative health care models not only alleviate hospital pressure but also potentially reduce hospital-acquired infections, length of stay, and overall health care expenditure. However, a reliable cost analysis of these models remains a priority.

Reference url

Recent Posts

biosimilars price competition
      

The Impact of MFN Pricing on the U.S. Biosimilar Market

💊 Could MFN Pricing Undermine Biosimilars?

MFN drug pricing aims to cut costs—but its indirect pressure on biosimilars may reduce competition (create a void) and raise long-term prices.

Explore the risks and what stakeholders can do to protect market sustainability.

#SyenzaNews #Biosimilars #DrugPricing #HealthPolicy #Pharma #MarketAccess

EU AI Act Healthcare Compliance
     

Navigating EU AI Act Healthcare Compliance: Proactive Steps for Ethical AI Integration

🔍 Are you prepared for the upcoming EU AI Act in healthcare?

As the first comprehensive AI regulation globally rolls out, healthcare organizations must move beyond mere compliance. The urgency lies in embedding ethical, trusted, and sustainable AI practices into every facet of healthcare AI. Early adoption of ethical assessments and collaboration is essential to navigate the complex regulatory landscape before the August 2026 deadline.

Learn about proactive compliance strategies that not only meet regulatory standards but also enhance patient trust and system efficacy!

#SyenzaNews #AIinHealthcare #HealthcareInnovation #DigitalTransformation

hepatitis vaccine uptake
         

Hepatitis Vaccine Uptake: Trends, Challenges, and the Role of Pharmacists

💉 Are we doing enough to bridge the gap in hepatitis vaccine uptake?

A recent article highlights that while over 90% of children are vaccinated against hepatitis B, adult rates are alarmingly low, posing a significant public health risk. Jeff Goad from the National Foundation for Infectious Diseases emphasizes the crucial role pharmacists can play in increasing access and dispelling common misconceptions about vaccines.

Join the conversation on enhancing vaccination strategies for better health outcomes!

#SyenzaNews #Healthcare #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.